Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the US for the treatment of type 1 and 2 diabetes

9 December 2015 - Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes.

For more details, go to: http://www.novonordisk.com/media/news-details.1972083.html

Michael Wonder

Posted by:

Michael Wonder